BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie Tompers Frederick, Adriano Piris, Alexandria P. Cogdill et al. · Clinical Cancer Research · 2013
PURPOSE: To evaluate the effects of BRAF inhibition on the tumor microenvironment in patients with metastatic melanoma. EXPERIMENTAL DESIGN: Thirty-five biopsies were collected from 16 patients with metastatic melanoma pretreatment (day 0) and at 10 to 14 days after initiation of treatment with either BRAF inhibitor alone (vemurafenib) or BRAF + MEK inhibition (dabrafenib + trametinib) and were also taken at time of progression. Biopsies were analyzed for melanoma antigens, T-cell markers, and immunomodulatory cytokines. RESULTS: Treatment with either BRAF inhibitor alone or BRAF + MEK inhibitor was associated with an increased expression of melanoma antigens and an increase in CD8+ T-cell infiltrate. This was also associated with a decrease in immunosuppressive cytokines [interleukin (IL)-6 and IL-8] and an increase in markers of T-cell cytotoxicity. Interestingly, expression of exhaustion markers TIM-3 and PD1 and the immunosuppressive ligand PDL1 was increased on treatment. A decrease in melanoma antigen expression and CD8 T-cell infiltrate was noted at time of progression on BRAF inhibitor alone and was reversed with combined BRAF and MEK inhibition. CONCLUSIONS: Together, these data suggest that treatment with BRAF inhibition enhances melanoma antigen expression and facilitates T-cell cytotoxicity and a more favorable tumor microenvironment, providing support for potential synergy of BRAF-targeted therapy and immunotherapy. Interestingly, markers of T-cell exhaustion and the immunosuppressive ligand PDL1 are also increased with BRAF inhibition, further implying that immune checkpoint blockade may be critical in augmenting responses to BRAF-targeted therapy in patients with melanoma.
Cited by 942 works. doi:10.1158/1078-0432.ccr-12-1630 Open-access PDF
Authors
- Dennie Tompers Frederick
- Adriano Piris
- Alexandria P. Cogdill
- Zachary Aaron Cooper
- Cecilia M. Lezcano
- Cristina R. Ferrone
- Devarati Mitra
- Andrea Boni
- Lindsay P. Newton
- Chengwen Liu
- Weiyi Peng
- Ryan Joseph Sullivan
- Donald P. Lawrence
- Frank Stephen Hodi
- Willem W. Overwijk
- Gregory A. Lizee
- Gëorge F. Murphy
- Patrick Hwu
- Keith T. Flaherty
- David E. Fisher
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Cancer Statistics, 2009
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion